000			05214cam a2200457M 4500
001			96606
003			ES-MaUEC
005			20230102112802.0
006			m o d
007			cr |n|||||||||
008			170815t20172017sz o 000 0 eng d
020			_a3319600168 _q(electronic bk.)
020			_a9783319600161 _q(electronic bk.)
020			_z3319600141
020			_z9783319600147
040			_aYDX _beng _cYDX _dN$T _dEBLCP _dGW5XE _dOCLCF _dUAB _dAZU _dUPM _dMERER _dGZM _dESU _dOCLCO _dIOG _dOCLCO _dNJR _dCOO _dJG0 _dOCLCO _dOCLCA _dES-MaUEC _bspa
050		4	_aRM315 _b2017 EB
245	0	0	_aNon-medical and illicit use of psychoactive drugs _cSuzanne Nielsen, Raimondo Bruno, Susan Schenk, editors.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2017
264		4	_c2017
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF
490	0		_aCurrent Topics in Behavioral Neurosciences _x1866-3370 _vvolume 34
500			_a _bSpringer Biomedical and Life Sciences eBooks 2017 English+International
505	0		_aPreface; New Directions in Substance Use-the Blurring of the Lines between Illicit and Therapeutic Drugs; Non-medical Use of Therapeutic Substances; New Ways of Approaching 'Illicit Drugs'; Future Directions; References; Contents; 447 Preclinical Effects of Antipsychotic Drugs; Abstract; 1 Introduction; 2 The Binding Profile of Antipsychotics; 3 Behavioural Test for the Therapeutic Effects of Antipsychotics; 4 Antipsychotic Drugs and Drug Discrimination; 5 Behavioural Tests for the Side Effect of Antipsychotics; References
505	8		_a421 Contribution of Impulsivity and Serotonin Receptor Neuroadaptations to the Development of an MDMA ('Ecstasy') Substance Use DisorderAbstract; References; 448 The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research; Abstract; 1 Brief Historical View of Opioid Abuse Potential Evaluation; 2 Abuse Potential Evaluation: Methods; 3 Full Mu Opioid Agonists; 4 Mu Opioid Partial Agonists; 4.1 Buprenorphine: A Case Study; 5 Mixed Opioid Agonists/Antagonists; 6 Atypical Opioid Agonists; 6.1 Abuse-Deterrent Formulations (ADFs) and Abuse Potential Testing
505	8		_a470 Injection of Pharmaceuticals Designed for Oral Use: Harms Experienced and Effective Harm Reduction Through FiltrationAbstract; 1 Introduction: Illicit Injection of Pharmaceuticals; 2 Thrombosis and Inflammation; 3 Embolism and Ischaemia; 4 Injection Site and Blood Vessels; 5 Pulmonary System; 6 Infections; 7 Filtration as a Harm Reduction Measure; 8 General Filtering Study Methodology; 8.1 Survey of People Who Inject Drugs; 8.2 Drug Extraction and Filtration; 8.3 Analysis of Particle Content; 8.4 Analysis of Active Drug Content; 8.5 Drugs Examined; 8.6 Bacterial Suspension; 9 Results
505	8		_a7 SummaryReferences; 422 Over-the-Counter Codeine-from Therapeutic Use to Dependence, and the Grey Areas in Between; Abstract; 1 Codeine Pharmacology; 2 Codeine Availability; 3 Non-medical Use and Dependence; 4 Harms from High-Dose Consumption of Over-the-Counter Codeine; 4.1 Evidence for Effectiveness; 5 Responses to Problematic Over-the-Counter Codeine Use; 5.1 Increased Restrictions on Sales; 5.2 Harm Reduction; 5.3 Challenges for Pharmacists; 5.4 Screening and Brief Intervention; 5.5 Monitoring of Sales as Part of a Comprehensive Response; Funding Acknowledgement; References
505	8		_a9.1 Filtration Methods Used by PWID9.2 Particulate Contamination Following Filtration; 10 Summary and Conclusions; Acknowledgements; References; 426 Misuse of Methylphenidate; Abstract; 1 Introduction; 1.1 Attention-Deficit/Hyperactivity Disorder (ADHD); 1.2 Link Between ADHD Neurobiology, Medication Mechanism, and Abuse Potential; 1.3 Prevalence of ADHD Stimulant Medication Misuse; 2 Methylphenidate Misuse; 2.1 Methylphenidate Abuse Liability; 2.2 Methylphenidate Diversion and Misuse; 2.3 Methylphenidate Misuse Safety Concerns; 3 Discussion; 3.1 Malingering
520	3		_aThis volume is devoted to descriptions of non medical as well as medical uses for some drugs that have typically, or not so typically, been associated with drug abuse. One major objective of this book is to identify costs and benefits of drug abuse. The book highlights drugs including 3,4 methylenedioxymethamphetamine (MDMA), cannabinoids, opioids and methylphenidate because of their well-documented potential for abuse and provides new and emerging evidence of their potential to treat some chronic disease states alongside the potential consequences of exposure. .
650		7	_aDrogas _xConsumo _2embne _0(OCoLC)fst00898480 _0 _9169029
700	1		_aBruno, Raimondo,. _eeditor literario
700	1		_aNielsen, Suzanne, _eeditor literario
700	1		_aSchenk, Susan, _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-60016-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aEBOOK, asignarmaterias, EBSPRINGER_2017
998			_b02/2018 _dz _e- _zSI
999			_c96606 _d96606 _x1